MX351189B - Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares. - Google Patents

Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares.

Info

Publication number
MX351189B
MX351189B MX2014001764A MX2014001764A MX351189B MX 351189 B MX351189 B MX 351189B MX 2014001764 A MX2014001764 A MX 2014001764A MX 2014001764 A MX2014001764 A MX 2014001764A MX 351189 B MX351189 B MX 351189B
Authority
MX
Mexico
Prior art keywords
alpha1
delaying
onset
progression
proteinase inhibitor
Prior art date
Application number
MX2014001764A
Other languages
English (en)
Other versions
MX2014001764A (es
Inventor
Mark Forshag
Royce Waltrip
Les Garlinghouse
William Barnett
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of MX2014001764A publication Critical patent/MX2014001764A/es
Publication of MX351189B publication Critical patent/MX351189B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0018—Details of inhalators; Constructional features thereof with exhalation check valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un inhibidor de Alpha1-proteinasa (A1P1) para usarse en disminuir la progresión de uno o más de un primer conjunto de síntomas asociados con exacerbaciones pulmonares de empeoramiento y/o aumento de la severidad en un individuo en necesidad del mismo. Uso de inhibidor de Apha1-proteinasa (A1P1) para preparar un medicamento para disminuir la progresión de uno o más de un primer conjunto de síntomas asociados con exacerbaciones pulmonares de empeoramiento y/o aumento de la severidad en un individuo en necesidad del mismo.
MX2014001764A 2011-12-30 2012-11-22 Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares. MX351189B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161581708P 2011-12-30 2011-12-30
PCT/IB2012/056616 WO2013098672A2 (en) 2011-12-30 2012-11-22 Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations

Publications (2)

Publication Number Publication Date
MX2014001764A MX2014001764A (es) 2014-04-30
MX351189B true MX351189B (es) 2017-10-04

Family

ID=47470050

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001764A MX351189B (es) 2011-12-30 2012-11-22 Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares.

Country Status (19)

Country Link
US (1) US9421248B2 (es)
EP (1) EP2758065B1 (es)
JP (4) JP2015504051A (es)
KR (1) KR20140108516A (es)
CN (2) CN103889436A (es)
AR (2) AR088971A1 (es)
AU (1) AU2012337241B2 (es)
BR (1) BR112014007127A2 (es)
CA (1) CA2844878C (es)
CL (1) CL2014000722A1 (es)
ES (1) ES2887358T3 (es)
HK (1) HK1198918A1 (es)
IL (1) IL231109B (es)
MX (1) MX351189B (es)
MY (1) MY166314A (es)
RU (1) RU2635482C2 (es)
SG (2) SG2014012066A (es)
UY (1) UY34465A (es)
WO (1) WO2013098672A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160054475A (ko) * 2013-08-05 2016-05-16 제라드 뵈르만 흡연의 해로운 영향을 감소시키는 신규의 수단
JP6783767B2 (ja) * 2014-12-22 2020-11-11 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 組換えタンパク質を精製する方法
US11446366B2 (en) * 2015-02-05 2022-09-20 Canem Holdings, Llc Compositions and methods for treating granulomatosis with polyangiitis
WO2018154568A1 (en) * 2017-02-21 2018-08-30 Kamada Ltd. Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases
US10663434B2 (en) * 2017-03-31 2020-05-26 Sonix, Inc. Wafer chuck
WO2021028927A1 (en) * 2019-08-15 2021-02-18 Kamada Ltd Combination of alpha-1-antitrypsin and steroids and uses therefor
JP2022544834A (ja) * 2019-08-23 2022-10-21 ピーエイチ・ファーマ・カンパニー・リミテッド 肺疾患における好中球エラスターゼ阻害剤の使用
US20230302104A1 (en) * 2020-05-01 2023-09-28 Atlas Biotechnology S.A. Treatment and/or prevention of a disease or a syndrome related to a virus infection

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE395611B (sv) 1975-12-12 1977-08-22 Draco Ab Aerosolinhalationsanordning avsedd for inhalering genom ett inhaleringsmunstycke av farmakologiskt aktiva substanser
SE411705B (sv) 1976-11-09 1980-02-04 Draco Ab Anordning for generering av en avskermad, vesentligen drivmedelsfri aerosol
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4667688A (en) 1983-11-28 1987-05-26 Francisco Roig Mini pack of cigarettes
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
JP2599585B2 (ja) 1984-06-19 1997-04-09 トランスジ−ン ソシエテ アノニム ヒトα▲下１▼−アンチトリプシン誘導体及びその製造法
US4697003A (en) 1985-11-01 1987-09-29 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US5114917A (en) 1986-12-24 1992-05-19 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US5915378A (en) 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
DK0748213T3 (da) 1994-03-07 2004-08-02 Nektar Therapeutics Fremgangsmåder og sammensætninger til pulmonal indgivelse af insulin
CA2190502A1 (en) 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
AU6884396A (en) 1995-09-07 1997-03-27 Ppl Therapeutics (Scotland) Ltd Purification of alpha-1 proteinase inhibitor
US5780440A (en) 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
PL343276A1 (en) 1998-03-16 2001-08-13 Inhale Therapeutic Syst Aerosolized active agent delivery
US6093804A (en) 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US6397838B1 (en) 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
DE19953317C1 (de) * 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
WO2002050287A2 (en) 2000-12-18 2002-06-27 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
WO2005027821A2 (en) 2003-09-22 2005-03-31 Kamada Ltd. Large scale preparation of alpha-1 proteinase inhibitor and use thereof
ATE530165T1 (de) * 2003-11-14 2011-11-15 Baxter Int Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
US7914771B2 (en) 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
EP2740487B1 (en) * 2006-02-09 2018-02-28 Kamada Ltd. Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases
US20080078382A1 (en) 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
EP1927373B1 (en) 2006-11-30 2012-08-22 PARI Pharma GmbH Inhalation nebulizer
NZ590257A (en) 2008-07-18 2012-08-31 Grifols Therapeutics Inc Method of preparing alpha-1 proteinase inhibitor
ES2679819T3 (es) 2009-11-03 2018-08-31 Grifols Therapeutics Inc. Composición, método y kit para inhibidor de alfa-1 proteinasa

Also Published As

Publication number Publication date
CN107596359A (zh) 2018-01-19
AR116887A2 (es) 2021-06-23
ES2887358T3 (es) 2021-12-22
SG2014012066A (en) 2014-09-26
EP2758065A2 (en) 2014-07-30
US9421248B2 (en) 2016-08-23
AR088971A1 (es) 2014-07-23
MX2014001764A (es) 2014-04-30
CA2844878A1 (en) 2013-07-04
UY34465A (es) 2013-07-31
AU2012337241A1 (en) 2013-07-18
RU2014106758A (ru) 2015-08-27
US20150011460A1 (en) 2015-01-08
CN103889436A (zh) 2014-06-25
NZ621596A (en) 2016-08-26
RU2635482C2 (ru) 2017-11-13
MY166314A (en) 2018-06-25
SG10201610913PA (en) 2017-02-27
EP2758065B1 (en) 2021-06-23
JP2018104439A (ja) 2018-07-05
KR20140108516A (ko) 2014-09-11
JP2017039745A (ja) 2017-02-23
BR112014007127A2 (pt) 2017-04-04
WO2013098672A2 (en) 2013-07-04
CL2014000722A1 (es) 2014-10-10
IL231109B (en) 2018-02-28
AU2012337241B2 (en) 2016-10-13
HK1198918A1 (en) 2015-06-19
WO2013098672A3 (en) 2013-10-24
IL231109A0 (en) 2014-04-30
JP2019135243A (ja) 2019-08-15
CA2844878C (en) 2017-11-28
JP2015504051A (ja) 2015-02-05

Similar Documents

Publication Publication Date Title
MX355728B (es) Inhibidores de cinasas.
MX351189B (es) Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares.
HK1213251A1 (zh) 作為突變 抑制劑的 -嘧啶- -基-噁唑烷- -酮化合物
PH12015502141A1 (en) Substituted xanthines and methods of use thereof
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
EP3113772A4 (en) Human plasma kallikrein inhibitors
EP2714081A4 (en) METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX2013010475A (es) Composiciones inmunoterapeuticas de levadura-brachyuri.
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
MY168300A (en) Pharmaceutical Composition for Inhalation
EP3033101A4 (en) Methods for reducing exacerbation rates of asthma using benralizumab
IN2014CN04050A (es)
CA2843611C (en) Compositions and methods for reducing the incidence of equine digestive disorders
EP3244968A4 (en) Combination therapy for pulmonary hypertension
IN2014CN00312A (es)
EP3182983A4 (en) Antibodies to polyphosphate decrease clot formation, decrease inflammation, and improve survival
WO2012106702A3 (en) Treatment of leukemia
WO2014008204A3 (en) Structures of proteasome inhibitors and methods for synthesizing and use thereof
WO2012139074A3 (en) Migrastatins and uses thereof
IN2014CN02585A (es)
EA201391421A1 (ru) Пролекарства d-гамма-глутамил-d-триптофана и d-гамма-глутамил-l-триптофана
EA201391419A1 (ru) Пролекарства d-изоглутамил-[d/l]-триптофана

Legal Events

Date Code Title Description
FG Grant or registration